{"version":"1.0","type":"rich","provider_name":"NULLPEN","provider_url":"https://nullpen.com","title":"Trial results posted: A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)","cache_age":300,"width":400,"height":320,"html":"<iframe src=\"https://nullpen.com/embed?story=sha256%3A5639e1e42c122a9164710927278da52d91411d7745953234d1f24b836b5c3b32\" title=\"Trial results posted: A Phase 3 Trial of Epcoritamab vs Investigator&apos;s Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)\" width=\"400\" height=\"320\" loading=\"lazy\" style=\"border:0;max-width:100%\" referrerpolicy=\"strict-origin-when-cross-origin\" sandbox=\"allow-popups allow-popups-to-escape-sandbox\"></iframe>"}